Featuring slide presentations and related discussion from Drs Susana Banerjee, Richard T Penson and Shannon Westin, including the following topics:

• Genetic Testing in Ovarian Cancer: Integration of PARP Inhibitor Maintenance into the Management of Newly Diagnosed BRCA Mutation-Positive Ovarian Cancer — Susana Banerjee, MBBS, MA, PhD (0:00)
• Clinical Utility of PARP Inhibitor Maintenance in Patients with BRCA Wild-Type Advanced Ovarian Cancer — Richard T Penson, MD, MRCP (42:11)
• PARP Inhibitors in Combination with Immunotherapeutic and Chemotherapeutic Agents in the Management of Advanced Ovarian Cancer — Shannon N Westin, MD, MPH (1:15:14)

CME information and select publications

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2021 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Susana Banerjee, Richard T Penson and Shannon Westin, including the following topics:

• Introduction (0:00)
• Case: A woman in her late 60s with recurrent serous papillary adenocarcinoma of the fallopian tube with a germline BRCA1 mutation — Yanjun Ma, MD (5:24)
• Case: A woman in her mid-60s with Stage IIIC fallopian tube carcinoma with no deleterious mutations — Lyndsay J Willmott, MD (9:11)
• Case: A woman in her late 70s with ovarian cancer (OC) and a germline BRCA2 mutation — Shachar Peles, MD (14:22)
• Case: A woman in her mid-40s with Stage IIIC serous OC and a germline BRCA1 mutation — Dr Wilmott (17:06)
• PARP inhibitor maintenance therapy (23:32)
• Case: A woman in her late 60s with Stage IV OC and a germline BRCA1 mutation — Laurie Matt-Amaral, MD, MPH (39:43)
• Case: A woman in her late 70s with Stage IIIC OC with a germline BRCA mutation who develops anemia on olaparib — Sulfi Ibrahim, MD (43:55)
• Niraparib-associated thrombocytopenia and surgical procedures — Heidi E Godoy, DO (47:14)
• Case: A woman in her mid-70s with recurrent OC and a germline and somatic BRCA2 mutation — Dana M Chase, MD (50:42)
• Novel strategies with PARP inhibitors in OC (53:38)

CME information and select publications

Featuring an interview with Dr Kevin Kalinsky, including the following topics:

• Genomic assays in early-stage breast cancer (0:00)
• Case: A woman in her early 30s with a family history of breast cancer is diagnosed with hormone receptor (HR)-positive disease and receives a 21-gene assay Recurrence Score® (RS) of 16 (35:08)
• Case: A woman in her early 60s with ER/PR-positive, HER2-negative breast cancer and a 21-gene RS of 11 receives a recommendation of radiation therapy and an aromatase inhibitor (38:45)
• Case: A woman in her mid-20s with ER-positive, PR-negative, HER2-negative breast cancer and axillary involvement receives a MammaPrint® high score (40:42)
• Design and key findings of the Phase III RxPONDER trial evaluating the role of chemotherapy for patients with ER-positive, HER2-negative early breast cancer with 1 to 3 positive lymph nodes and a 21-gene RS of 25 or lower (43:42)
• Benefit of chemotherapy for premenopausal versus postmenopausal patients enrolled in the RxPONDER trial (47:15)
• Predictors of late recurrence; use of ctDNA (circulating tumor DNA) as a biomarker of recurrence (51:40)
• Utility of the RSClin educational tool integrating the 21-gene RS and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit for patients with HR-positive, HER2-negative, node-negative breast cancer (56:59)
• Impact of the COVID-19 vaccine on screening for breast cancer (1:00:30)
• Perspective on the use of genomic assays in the neoadjuvant setting (1:02:41)
• Age-associated benefit from chemotherapy for women with luminal breast cancer in the MINDACT trial (1:06:53)

CME information and select publications

Featuring perspectives from Drs Joseph Chao and Yelena Y Janjigian on cases from the practice of Dr Daniel Catenacci, including the following topics:

• Introduction (0:00)
• A man in his mid-50s with HER2-negative, microsatellite stable (MSS) metastatic gastroesophageal junction (GEJ) adenocarcinoma with a PD-L1 combined positive score (CPS) of 20 (6:11)
• A man in his mid-50s with MSS localized adenocarcinoma of the esophagus with a PD-L1 CPS of 10 (13:56)
• A man in his late 60s with relapsed HER2-positive, MSS adenocarcinoma of the esophagus with a PD-L1 CPS of 0 (24:59)
• A woman in her mid-30s with relapsed HER2-positive metastatic gastric cancer who experiences rapid disease progression while receiving trastuzumab deruxtecan (46:38)
• A man in his late 60s with newly diagnosed FGFR2b-overexpressing metastatic GEJ adenocarcinoma who receives the investigational agent bemarituzumab in combination with modified FOLFOX6 (51:30)

CME information and select publications

Featuring perspectives from Drs Alexander Perl and Eunice S Wang, including the following topics:

• Introduction (0:00)
• Venetoclax combinations in the treatment of acute myeloid leukemia (AML) (5:15)
• Role of FLT3 inhibitors in the treatment of AML (28:08)
• Use of IDH inhibitors to treat AML (48:32)
• Oral azacitidine (CC-486) in the treatment of AML (54:26)
• Treatment with CPX-351 for patients with secondary AML (56:18)
• Novel agents and strategies in the treatment of AML (58:08)

CME and select publications

Featuring perspectives from Dr Joyce O'Shaughnessy on following topics:

• Introduction (0:00)
• Case Presentations from Alan B Astrow, MD on Chemotherapy for Triple-Negative Breast Cancer (TNBC)
• • A woman in her late 80s with triple-negative lobular carcinoma (1:54)
  • A woman in her mid-60s with triple-negative, node-positive breast cancer (6:30)
  • A woman in her early 30s with triple-negative, node-negative infiltrating ductal carcinoma (IDC) (14:39)
• San Antonio Breast Cancer Symposium (SABCS®) Review — Immunotherapy for Advanced TNBC (20:25)
• Case Presentations from Dr Astrow and SABCS Review of Data on Immunotherapy Combinations and PARP Inhibition for TNBC
• • A woman in her early 40s with metastatic TNBC (31:08)
  • A woman in her early 60s with a germline BRCA1 mutation and locally advanced breast cancer (36:14)
• Case Presentations from Dr Astrow on Triple-Negative Small Cell Carcinoma of the Breast and Triple-Negative IDC; Sacituzumab Govitecan for Patients with TNBC
• • A woman in her mid-40s with triple-negative small cell carcinoma of the breast (48:11)
  • A woman in her late 30s with triple-negative IDC (51:44)

CME information and select publications

Featuring perspectives from Dr Mark D Pegram on the following topics:

• Case presentations and San Antonio Breast Cancer Symposium (SABCS®) review of locally advanced and high-risk HER2-positive breast cancer
• • Introduction (0:00)
  • Case: A 49-year-old woman who received neoadjuvant TCHP, currently awaiting surgery — Estelamari Rodriguez, MD, MPH (5:12)
  • Case: A 55-year-old woman with Stage I HER2-positive breast cancer — Kelly Yap, MD (23:46)
  • Case: A 45-year-old woman who received postoperative T-DM1 after neoadjuvant TCHP — Philip Glynn, MD (26:30)
  • Case: A 39-year-old woman with localized disease and a positive cervical node on PET scan — Dr Rodriguez (32:00)
• Case presentations and SABCS review of metastatic HER2-positive breast cancer
• • Case: A 70-year-old woman with a 10-cm Grade III, ER/PR-negative, HER2-positive infiltrating ductal carcinoma and pleural metastases — Alan B Astrow, MD (38:24)
  • Case: An 87-year-old woman with pretreated HER2-positive metastatic breast cancer now with negative (low) HER2 — Yanjun Ma, MD (43:25)
  • Case: A 60-year-old woman with malignant pericardial effusion — Dr Glynn (50:23)
  • Case: A 43-year-old woman who develops brain metastases after prior TCHP — Dr Yap (53:09)

CME information and select publications

Proceedings from the first in a 2-part nursing webinar series. Featuring perspectives from Ms Rhonda Hewitt and Dr Mark Levis, including the following topics:

• Introduction (0:00)
• Case: A man in his early 80s with newly diagnosed poor-risk acute myeloid leukemia (AML) — Rhonda Hewitt, MSN, ANP, AOCNP (1:08)
• Molecular evaluation of patients with newly diagnosed AML (15:21)
• Venetoclax combinations for AML and management of tumor lysis syndrome (22:14)
• Case: A man in his early 80s with AML and a FLT3 ITD mutation — Mark Levis, MD, PhD (37:15)
• Management of AML with a FLT3 mutation (40:59)
• Management of AML with an IDH mutation (51:07)
• Other novel agents and strategies for AML (56:26)

CME information and select publications

Featuring an interview with Dr Morie A Gertz, including the following topics:

• Recent advances in the treatment of amyloid light chain (AL) amyloidosis (0:00)
• Case: A woman in her late 70s receiving medical care for monoclonal gammopathy of undetermined significance (MGUS) is diagnosed with AL amyloidosis (22:12)
• Case: A man in his late 70s being monitored for multiple myeloma after a diagnosis of smoldering multiple myeloma is found to have AL amyloidosis (25:04)
• Case: A man in his early 70s with amyloidosis with peripheral neuropathy receives a misdiagnosis of MGUS (26:29)
• Pathophysiology and diagnosis of AL amyloidosis (28:32)
• Case: A woman in her late 70s being monitored for MGUS is found to have AL amyloidosis (34:37)
• Design, eligibility criteria and key endpoints of the Phase III ANDROMEDA study evaluating subcutaneous daratumumab in combination with CyBorD versus CyBorD alone for patients with newly diagnosed AL amyloidosis (39:22)
• Activity and tolerability of pomalidomide, venetoclax or isatuximab in patients with AL amyloidosis (47:48)
• Mechanism of action and efficacy of CAEL-101, an antibody targeting light chain amyloid fibrils, for AL amyloidosis (53:48)
• Selection and sequencing of therapy for patients with AL amyloidosis (56:17)

CME information and select publications

Featuring an interview with Dr Mitesh J Borad, including the following topics:

• Novel Targeted Approaches in Cholangiocarcinoma (0:00)
• Case: A woman in her late 60s with intrahepatic cholangiocarcinoma and an FGFR2 fusion (24:34)
• Case: A man in his late 70s with intrahepatic cholangiocarcinoma and an IDH1 mutation (26:30)
• Case: A man his late 60s with microsatellite instability-high intrahepatic cholangiocarcinoma (27:33)

CME information and select publications